CSIRO Publishing blank image blank image blank image blank imageBooksblank image blank image blank image blank imageJournalsblank image blank image blank image blank imageAbout Usblank image blank image blank image blank imageShopping Cartblank image blank image blank image You are here: Journals > Sexual Health   
Sexual Health
Journal Banner
  Publishing on sexual health from the widest perspective
 
blank image Search
 
blank image blank image
blank image
 
  Advanced Search
   

Journal Home
About the Journal
Editorial Committee
Contacts
Content
Online Early
Current Issue
Just Accepted
All Issues
Special Issues
Sample Issue
For Authors
General Information
Instructions to Authors
Submit Article
Open Access
For Referees
Referee Guidelines
Review an Article
Annual Referee Index
For Advertisers
For Subscribers
Subscription Prices
Customer Service

blue arrow e-Alerts
blank image
Subscribe to our Email Alert or RSS feeds for the latest journal papers.

red arrow Connect with us
blank image
facebook twitter youtube

red arrow Interview with Kit Fairley
blank image
Hear Kit Fairley speak about what is sexual health.

 

Article << Previous     |     Next >>   Contents Vol 6(3)

The incidence of genital warts in Australian women prior to the national vaccination program

Julia M. L. Brotherton A C, Anita Heywood A, Stella Heley B

A National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children’s Hospital at Westmead and the University of Sydney, Westmead, NSW 2145, Australia.
B Victorian Cytology Service and Melbourne Sexual Health Centre, Carlton, Vic. 3053, Australia.
C Corresponding author. Email: jbrother@vcs.org.au
 
PDF (251 KB) $25
 Export Citation
 Print
  


Abstract

The quadrivalent human papillomavirus (HPV) vaccine currently being delivered to Australian women aged 12–26 years under the National HPV Vaccination Program promises to substantially reduce the incidence of genital warts. We review what is known about the burden of genital warts among Australian women. Incidence appears to peak among women aged 20–24 years, of whom 1.4% report genital warts in the previous year and who are hospitalised for treatment at a rate of 26 per 100 000. A surveillance system capable of documenting any decrease in the incidence of genital warts and recurrent respiratory papillomatosis after vaccination is urgently required.

Keywords: burden of disease, hospitalisations, human papillomavirus, juvenile onset recurrent respiratory papillomatosis, prevalence, surveillance.


   
Subscriber Login
Username:
Password:  

    
Legal & Privacy | Contact Us | Help

CSIRO

© CSIRO 1996-2014